Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Athira Pharma, Inc. (ATHA : NSDQ)
 
 • Company Description   
Athira Pharma Inc. is a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration. Athira Pharma Inc. is based in SEATTLE.

Number of Employees: 26

 
 • Price / Volume Information   
Yesterday's Closing Price: $0.34 Daily Weekly Monthly
20 Day Moving Average: 172,208 shares
Shares Outstanding: 39.04 (millions)
Market Capitalization: $13.27 (millions)
Beta: 2.99
52 Week High: $3.67
52 Week Low: $0.22
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -5.56% -9.75%
12 Week 36.00% 16.16%
Year To Date -42.05% -45.72%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
18706 North Creek Parkway Suite 104
-
Bothell,WA 98011
USA
ph: 425-620-8501
fax: -
ir@athira.com http://www.athira.com
 
 • General Corporate Information   
Officers
Mark Litton - President; Chief Executive Officer and Director
Kelly A. Romano - Chairwoman of the Board of Directors
Robert Renninger - Senior Vice President; Finance and Accounting
Joseph Edelman - Director
James A. Johnson - Director

Peer Information
- (-)
- (-)
- (-)
- (-)
- (-)
- (-)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 04746L104
SIC: 2836
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/25
Next Expected EPS Date: 08/07/25
Share - Related Items
Shares Outstanding: 39.04
Most Recent Split Date: (:1)
Beta: 2.99
Market Capitalization: $13.27 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.17 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-0.76 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/07/25  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 0.36
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: 66.67%
vs. Previous Quarter: 41.03%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
ROE
06/30/25 - -
03/31/25 - -142.99
12/31/24 - -132.57
ROA
06/30/25 - -
03/31/25 - -106.40
12/31/24 - -99.49
Current Ratio
06/30/25 - -
03/31/25 - 7.26
12/31/24 - 4.18
Quick Ratio
06/30/25 - -
03/31/25 - 7.26
12/31/24 - 4.18
Operating Margin
06/30/25 - -
03/31/25 - -
12/31/24 - -
Net Margin
06/30/25 - -
03/31/25 - -
12/31/24 - -
Pre-Tax Margin
06/30/25 - -
03/31/25 - -
12/31/24 - -
Book Value
06/30/25 - -
03/31/25 - 0.96
12/31/24 - 1.16
Inventory Turnover
06/30/25 - -
03/31/25 - -
12/31/24 - -
Debt-to-Equity
06/30/25 - -
03/31/25 - 0.00
12/31/24 - 0.00
Debt-to-Capital
06/30/25 - -
03/31/25 - 0.00
12/31/24 - 0.00
 

Powered by Zacks Investment Research ©